Ondine Biomedical enters 2026 at a decisive stage in its development. The company is positioning Steriwave, its light activated antimicrobial technology, as a non antibiotic approach to reducing hospital acquired
Ondine Biomedical enters 2026 at a decisive stage in its development. The company is positioning Steriwave, its light activated antimicrobial technology, as a non antibiotic approach to reducing hospital acquired






